Tag: G3 Therapeutics

Little (a), Big Risk: G3 Therapeutics Sets Out to Unravel Lp(a)-Driven Cardiovascular Disease (Lipoprotein(a)-Driven Cardiovascular Disease)

Coronary/Structural Heart by Comments are Disabled

G3 is trailblazing the next frontier of cardiovascular disease SAN FRANCISCO, Jan. 4, 2024 /PRNewswire/ — G3 Therapeutics (“G3”), a global leader in the use of multiomic biological Big Data, has initiated a groundbreaking initiative to unravel the contribution of Lipoprotein(a) [“Lp(a)”]…

Continue Reading →

Aitia and G3 Therapeutics Publish Results Identifying New Causal Biomarkers of Atherosclerotic Coronary Artery Disease (ASCAD), the Leading Cause of Morbidity and Mortality Worldwide

Coronary/Structural Heart by 0 comments

Triglyceride-rich LDL particles were found to be directly causal in ASCAD based on Aitia’s Digital Twins built on G3’s Global Multi-omic Clinical Study Data and Aitia’s Causal AI Technology LDL-Triglycerides may become an important diagnostic biomarker in ASCAD and may lead to new therapeutics ATLANTA and SOMERVILLE, Mass., Jan. 12, 2023 /PRNewswire/ — G3 […]

Continue Reading →